PAVmed Subsidiary Lucid Diagnostics Partners with University of Pennsylvania to Evaluate EsoCheck™ in Eosinophilic Esophagitis (EoE) Patients
PAVmed Inc. (PAVM)
US:NASDAQ Investor Relations:
ir.pavm.com
Company Research
Source: GlobeNewswire
Study to assess EsoCheck as a less invasive, more efficient, and cost-effective alternative to endoscopic biopsies for rapidly emerging allergy-mediated condition which currently requires multiple and frequent invasive endoscopies NEW YORK, March 02, 2020 (GLOBE NEWSWIRE) -- PAVmed Inc. (Nasdaq: PAVM, PAVMZ) (the “Company” or “PAVmed”), a highly differentiated, multiproduct medical device company, today announced that its majority owned subsidiary, Lucid Diagnostics Inc. (“Lucid”), has entered into a clinical trial research agreement with the University of Pennsylvania (“Penn”) for a clinical trial designed to evaluate whether Lucid’s EsoCheck™ Esophageal Cell Collection Device with Collect+Protect™ Technology (“EsoCheck”) provides a less invasive, more efficient, and cost-effective alternative to endoscopic biopsies in the management of patients with Eosinophilic Esophagitis. Eosinophilic esophagitis (EoE) is a rapidly emerging allergy-mediated inflammatory condition of the esoph
Show less
Read more
Impact Snapshot
Event Time:
PAVM
Last Price
Price Change
Price Change%
Volume Shares
Max Up
Max Down
%
Volume Ratio
Performance Comparison
Updated
|
Event Day
Stock performance from the time of news release until the following 4pm ET market close
|
Last price at news event
|
Since Event
Multi-day stock performance from the time of the news release
|
|---|---|---|
|
EVENT DAY
Stock performance from the time of news release until the following 4pm ET market close
|
LAST
PRICE AT NEWS EVENT |
SINCE EVENT
Multi-day stock performance from the time of the news release
|
| Last Price | ||
| VWAP | ||
|
High:
|
Max Up |
High:
|
|
Low:
|
Max Down |
Low:
|
|
%
|
Post news range |
%
|
|
|
Price change |
|
|
|
Price Change Percentage |
|
|
|
S&P 500 (SPX) |
|
|
%
|
Volume ratio |
%
|
| Volume | ||
| Ticks | ||
|
|
Avg transaction size |
|
Don't Miss Out On The Next BIG Stock Move
Event day
Event Day Chart will not be displayed beyond 90-day period of the event
Performance since event
Time And Velocity Analysis
Be the first to know
Opt in for alerts from News Quantifed
Sign Up Today
Opt-in for
PAVM alerts
Learn More With NQ
Reading the Impact Report
Help Me Understand This Data
Help Me Understand This Data
How NQ Works
What is news-based trading?
And why is it so successful?
And why is it so successful?
Movers & Shakers
The biggest gainers and losers and WHY it moved
PAVM alerts
High impacting PAVmed Inc. news events
Weekly update
A roundup of the hottest topics
PAVM
News
- Lucid Diagnostics Submits Clinical Evidence Package to MolDX Seeking Medicare Coverage for EsoGuard® Esophageal DNA Test [Yahoo! Finance]Yahoo! Finance
- Lucid Diagnostics to Present at the Canaccord Genuity MedTech, Diagnostics and Digital Health & Services Forum [Yahoo! Finance]Yahoo! Finance
- PAVmed Inc (PAVM) Q3 2024 Earnings Call Highlights: Record Revenue and Strategic Restructuring [Yahoo! Finance]Yahoo! Finance
- PAVmed Inc. 2024 Q3 - Results - Earnings Call Presentation [Seeking Alpha]Seeking Alpha
- PAVmed Provides Business Update and Third Quarter 2024 Financial ResultsPR Newswire
PAVM
Earnings
- 11/14/24 - Beat
PAVM
Analyst Actions
- 9/10/24 - Ascendiant Capital
PAVM
Sec Filings
- 11/14/24 - Form SC
- 11/14/24 - Form 8-K
- 11/14/24 - Form 10-Q
- PAVM's page on the SEC website